Compounds > cl 387785

cl 387785 and pf 00299804

cl 387785 has been researched along with pf 00299804 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barf, T; Kaptein, A1
Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ1

Reviews

1 review(s) available for cl 387785 and pf 00299804

ArticleYear
Irreversible protein kinase inhibitors: balancing the benefits and risks.
    Journal of medicinal chemistry, 2012, Jul-26, Volume: 55, Issue:14

    Topics: Animals; Cell Line; Humans; Protein Kinase Inhibitors; Protein Kinases; Risk; Structure-Activity Relationship; Time Factors

2012

Other Studies

1 other study(ies) available for cl 387785 and pf 00299804

ArticleYear
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
    Journal of medicinal chemistry, 2013, Sep-12, Volume: 56, Issue:17

    Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship

2013